Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura

Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura

Rituximab 375 mg/m(2) weekly for four weeks has significant activity in patients with immune thrombocytopenia. We evaluated the activity of lower dose rituximab (100 mg iv weekly for 4 weeks) in 28 adults with idiopathic thrombocytopenic purpura. Overall (platelet count > 50 x 10(9)/L) and comple...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Francesco Zaja, Marta Lisa Battista, Maria Teresa Pirrotta, S. Palmieri, Marco Montagna, Nicola Vianelli, L. Marin, M. Cavallin, Monica Bocchia, Marzia Defina, M. Ippoliti, Felicetto Ferrara, Francesca Patriarca, Maria Antonietta Avanzini, Mario Regazzi, Michele Baccarani, Miriam Isola, Franca Soldano, Renato Fanin
Fformat: Artigo
Iaith:Saesneg
Cyhoeddwyd: 2008
Mynediad Ar-lein:https://doi.org/10.3324/haematol.12206
https://haematologica.org/article/download/4889/19734
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Rhyngrwyd

https://doi.org/10.3324/haematol.12206
https://haematologica.org/article/download/4889/19734

Eitemau Tebyg